C-Reactive protein and risk of ESRD: results from the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) [PDF]
, 2016 Background: To better understand a potential association of elevated C-reactive protein (CRP) level with progression of chronic kidney disease (CKD), we examined the relationship of CRP level with the development of end-stage renal disease (ESRD) in ...
Burdmann, Emmanuel A. +12 more
core +1 more source
Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care [PDF]
, 2012 Author can archive publisher's pdf. Free via Creative Commons: CC-BENCHTOBEDSIDE-2.0.
Nandra, KK, Patel, NSA, Thiemermann, C
core +1 more source
Correction of ischemic optic neuropathy in rats by carbamylated darbepoetin [PDF]
, 2018 The protective effects of carbamylated darbepoetin on the model of ischemic optic neuropathy in rats were revealed. To increase the effectiveness of pharmacological correction of experimental ischemic optic neuropathy in an experiment by using ...
Peresypkina, A. A.
core +2 more sources
Allergy, Asthma & Clinical Immunology, 2018 Background Recombinant human erythropoietin, such as epoetin alfa and darbepoetin alfa, is an important therapy for anemia due to chronic renal failure. Allergy to recombinant human erythropoietin and the need for desensitization are rare.
Jaime S. Rosa +3 more
doaj +1 more source
Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome. [PDF]
, 2011 Little is known about the effect of anemia correction with erythropoietin (EPO) on B-type natriuretic peptide (BNP) levels, NYHA class, and hospitalization rate.
Antonelli, G +7 more
core +1 more source
American Journal of Hematology, Volume 101, Issue 4, Page 784-793, April 2026.A novel erythropoietin (EPO) promoter mutation (c.‐136 G>A) causes autosomal dominant erythrocytosis via non‐renal expression of EPO. ABSTRACT We previously reported a five‐generation kindred with autosomal dominant erythrocytosis associated with a novel germline promoter variant in the erythropoietin (EPO) gene (EPO c.‐136 G>A).
Lucie Lanikova +10 more
wiley +1 more source
Staff Time and Motion Assessment for Administration of Erythropoiesis-Stimulating Agents: A Two-Phase Pilot Study in Clinical Oncology Practices [PDF]
, 2013 BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are used for the management of anaemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitant myelosuppressive chemotherapy.
Arletta van Breda +5 more
core +1 more source
Biopharmaceuticals for Cancer Treatment: An Update
Cancer Medicine, Volume 15, Issue 4, April 2026.ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath +6 more
wiley +1 more source
Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin. [PDF]
PLoS ONE, 2011 Human IgG1 Fc has been widely used as a bioconjugate, but exhibits shortcomings, such as antibody- and complement-mediated cytotoxicity as well as decreased bioactivity, when applied to agonistic proteins.
Se Jin Im +16 more
doaj +1 more source
Nephrology, Volume 31, Issue 4, April 2026.ABSTRACT There is limited evidence to guide optimal frequency of surveillance bloodwork for haemodialysis patients. In September 2023, surveillance bloodwork frequency was reduced from monthly to 6‐weekly across 4 Illawarra‐Shoalhaven dialysis units.
Daniel Hirsch +10 more
wiley +1 more source